Researchers evaluated the safety of the anti-epileptic medication, lamotrigine use during pregnancy on newborns and child development. Most of the current evidence on antiepileptic drug (AED) use in pregnant women and the resulting increased incidence of child malformation and neurodevelopmental delay refers to the older generation of AEDs. Lamotrigine is a newer generation AED […]
Scientists from RUDN University took an active part in the development of a chemical compound to stop convulsions during epileptic seizures. The results of the study were published in Chirality. Epilepsy is a chronic neuralgic disease that causes convulsive seizures in humans and other animals. The pathogenesis of this disease is paroxysmal discharges in […]
The US Food and Drug Administration (FDA) has approved use of the antiepileptic drug lacosamide (Vimpat, UCB) in tablets and oral solution (not intravenous injection) in children as young as 4 years with partial-onset seizures (POS), the company has announced. The FDA approved lacosamide in 2009 as adjunctive therapy and 2014 as monotherapy for adults […]
Several new Australian-developed medicines showing promise treating childhood epilepsy, stroke and autoimmune diseases have emerged from an unusual source: the fangs of venomous creatures. Big pharmaceutical companies are excited by results showing these new venom-drugs are often superior to man-made drugs, and they are starting to pour money into research.
Zogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome
Zogenix, Inc., a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today reported positive top-line results from its first Phase 3 trial (Study 1) for its investigational drug, ZX008 (low-dose fenfluramine hydrochloride), for the treatment of Dravet syndrome. The trial met its primary objective of demonstrating that ZX008, at […]
Zynerba Pharmaceuticals has reported that its cannabis-based epilepsy gel ZYN002 (cannabidiol [CBD] gel) has failed to meet the primary point in a phase 2 clinical trial. The trial dubbed as STAR 1 was held in 188 adult epilepsy patients with focal seizures across 14 sites in Australia and New Zealand. When compared to placebo, ZYN002 […]